Top 25 Companies in Coronary Drug Eluting Balloon Market: Strategic Overview and Future Trends (2026–2035)

Description

According to a research report published by Spherical Insights & Consulting, the Coronary Drug Eluting Balloon Market Size is projected to grow from USD 0.81 billion in 2025 to USD 1.97 billion by 2035, at a CAGR of 9.29% during the forecast period 2026–2035. Rising coronary artery disease prevalence, growing geriatric population, increasing demand for minimally invasive procedures, technological advancements in drug delivery, and expanding healthcare infrastructure are key factors driving Coronary Drug Eluting Balloon market growth.

 

Introduction

The Coronary Drug Eluting Balloon (DEB) market refers to specialized angioplasty devices designed to deliver antiproliferative drugs such as paclitaxel or sirolimus directly to coronary artery walls, preventing restenosis without leaving permanent implants. These balloons are manufactured using raw materials, including semi-compliant polymers, catheter shafts, and drug-coating excipients that enable controlled drug transfer. Market growth is driven by the rising prevalence of coronary artery disease, the increasing geriatric population, and the growing demand for minimally invasive procedures with improved patient outcomes. Applications include treatment of in-stent restenosis, small vessel disease, and complex coronary lesions across hospitals and cardiac care centers. Government initiatives supporting cardiovascular disease management programs, healthcare infrastructure expansion, and reimbursement frameworks further boost market adoption. Recent developments include regulatory approvals and new product launches, enhancing treatment effectiveness. Technological advancements focus on advanced coating techniques, uniform drug delivery mechanisms, and next-generation balloon designs, significantly improving safety, reducing recurrence rates, and enhancing overall procedural efficiency.

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

In March 2026, the global drug-coated balloons for coronary artery disease market witnessed increased product innovation and funding support, driving growth due to rising cardiovascular disease burden and expanding clinical adoption.

 

In December 2025, industry reports highlighted the rapid expansion of drug-eluting balloon technologies, with “leave-nothing-behind” strategies gaining traction and increasing adoption across coronary interventions globally.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Coronary Drug Eluting Balloon Market.

 

Market Segmentation

Global Coronary Drug Eluting Balloon Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Paclitaxel-Coated Balloons, Sirolimus-Coated Balloons), By Application (In-Stent Restenosis, Small Vessel Disease, Bifurcation Lesions, Others), By End User (Hospitals, Cardiac Catheterization Laboratories, Specialty Clinics), By Material Type (Semi-Compliant Balloons, Non-Compliant Balloons), By Distribution Channel (Direct Sales, Distributors), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Analysis and Forecast 2026–2035.

 

Global Coronary Drug Eluting Balloon Market Size & Statistics

• The Market Size for Coronary Drug Eluting Balloon Was Estimated to be worth USD 0.81 Billion in 2025.
• The Market is Going to Expand at a CAGR of 9.29% between 2026 and 2035.
• The Coronary Drug Eluting Balloon Market Size is anticipated to reach USD 1.97 Billion by 2035.
• Asia Pacific is expected to grow the fastest during the forecast period in the Coronary Drug Eluting Balloon Market.
• North America is expected to generate the highest demand during the forecast period in the Coronary Drug Eluting Balloon market.

 

Regional growth and demand                                     

Asia Pacific is expected to grow the fastest during the forecast period in the Coronary Drug Eluting Balloon market. The region’s rapid growth is driven by the rising prevalence of cardiovascular diseases, expanding healthcare infrastructure, and increasing adoption of minimally invasive cardiac procedures. Countries such as China, India, and Japan are focusing on improving access to advanced interventional cardiology treatments and upgrading hospital facilities. Government initiatives supporting cardiac care programs, growing medical tourism, and increasing awareness about early diagnosis and treatment are further accelerating the adoption of drug-eluting balloons across the region.

 

North America is expected to generate the highest demand during the forecast period in the Coronary Drug Eluting Balloon market. Demand is driven by a high burden of coronary artery disease, a strong presence of advanced healthcare systems, and early adoption of innovative medical technologies. Hospitals and cardiac centers across the United States and Canada are increasingly utilizing drug-eluting balloons for treating in-stent restenosis and complex lesions. Favorable reimbursement policies, continuous product innovations, and strong regulatory support further contribute to sustained market demand in the region.

 

In February 2025, the United States initiated a major clinical trial for a paclitaxel-coated balloon targeting coronary artery disease, accelerating innovation and regulatory progress in North America’s drug-eluting balloon market.

 

 

Top 10 Trends in the Coronary Drug Eluting Balloon Market

• Increasing preference for “leave-nothing-behind” treatment strategies
• Rising adoption in in-stent restenosis treatment
• Growing use in small vessel and complex coronary lesions
• Technological advancements in drug coating technologies
• Shift toward sirolimus-coated balloon innovations
• Expanding minimally invasive cardiac procedures
• Increasing clinical trials and regulatory approvals
• Rising demand in emerging healthcare markets
• Integration with advanced imaging and catheter technologies
• Strategic collaborations and product launches by key players

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Coronary Drug Eluting Balloon Market.

 

Top 5 Trends 

1. Increasing Preference for “Leave-Nothing-Behind” Strategies

The coronary drug eluting balloon market is witnessing strong growth due to increasing preference for treatment approaches that avoid permanent implants. These balloons deliver drugs directly to the arterial wall without leaving a stent, reducing long-term complications such as thrombosis. Physicians are increasingly adopting this approach for better vascular healing and improved patient outcomes, particularly in cases where stent placement is not ideal. This trend is expected to significantly influence future interventional cardiology practices.

 

2. Rising Adoption in In-Stent Restenosis Treatment

Drug eluting balloons are becoming a preferred solution for treating in-stent restenosis, a common complication following stent implantation. Their ability to inhibit neointimal hyperplasia without adding additional metal layers enhances their clinical value. Hospitals and cardiac centers are increasingly using these balloons due to their effectiveness, safety profile, and ability to reduce repeat procedures, making them a key driver in the market’s expansion.

 

3. Growing Use in Small Vessel and Complex Lesions

The application of drug eluting balloons is expanding in small vessel diseases and complex coronary lesions where stents may not be suitable. These balloons offer uniform drug delivery and minimize vessel trauma, making them highly effective in challenging anatomical conditions. As the prevalence of complex coronary cases increases globally, demand for such advanced treatment options continues to rise significantly.

 

4. Technological Advancements in Drug Coating Technologies

Continuous innovation in drug coating technologies is improving the efficiency and consistency of drug delivery. Advanced coatings ensure optimal drug transfer, better adhesion, and controlled release into the vessel wall. These improvements are enhancing clinical outcomes and reducing restenosis rates, encouraging wider adoption among healthcare providers and boosting market growth.

 

5. Shift Toward Sirolimus-Coated Balloon Innovations

While paclitaxel-coated balloons have dominated the market, there is a growing shift toward sirolimus-coated balloons due to their improved safety and efficacy profiles. Manufacturers are focusing on developing next-generation sirolimus-based technologies to address the limitations of earlier products. This transition is expected to reshape the competitive landscape and drive innovation in the coronary drug-eluting balloon market.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the Coronary Drug Eluting Balloon market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Coronary Drug Eluting Balloon Market.

 

Top 25 Companies Leading the Coronary Drug Eluting Balloon Market

1. Medtronic plc
2. Boston Scientific Corporation
3. B. Braun Melsungen AG
4. Biotronik SE & Co. KG
5. Terumo Corporation
6. Koninklijke Philips N.V.
7. Cardionovum GmbH
8. iVascular S.L.U.
9. Biosensors International Group, Ltd.
10. Acrostak AG
11. OrbusNeich Medical Company Limited
12. Lepu Medical Technology Co., Ltd.
13. MicroPort Scientific Corporation
14. Cook Medical
15. Abbott Laboratories
16. Endocor GmbH
17. Eurocor GmbH
18. Alvimedica (CID S.p.A.)
19. Hexacath
20. Balton Sp. z o.o.
21. Natec Medical Ltd.
22. Surmodics, Inc.
23. Translumina Therapeutics LLP
24. Concept Medical Inc.
25. Meril Life Sciences Pvt. Ltd.

 

1. Medtronic plc

Headquarters: Dublin, Ireland

Medtronic plc is a global leader in medical technology with a strong presence in interventional cardiology, including drug-coated and drug-eluting balloon solutions. The company focuses on developing advanced coronary intervention devices that improve patient outcomes through minimally invasive procedures. Its drug-eluting balloon technologies are designed to deliver precise drug dosing with optimized coating techniques, supporting treatment of in-stent restenosis and complex lesions. Medtronic invests heavily in clinical research, innovation, and global expansion, enabling widespread adoption of its cardiovascular solutions across developed and emerging markets.

 

2. Boston Scientific Corporation

Headquarters: Marlborough, Massachusetts, United States

Boston Scientific Corporation is a major player in the cardiovascular device market, offering a broad portfolio of interventional cardiology products, including drug-eluting technologies. The company emphasizes innovation in balloon catheter design and drug delivery systems to enhance treatment efficiency and safety. Its solutions are widely used in coronary artery disease treatment, particularly for complex lesions and restenosis cases. Boston Scientific’s strong R&D capabilities, global distribution network, and continuous product advancements support its leadership in the coronary drug eluting balloon market.

 

3. B. Braun Melsungen AG

Headquarters: Melsungen, Germany

Braun Melsungen AG is a leading healthcare company providing advanced medical devices, including drug-coated balloon catheters for coronary and peripheral interventions. The company focuses on high-quality manufacturing, innovative coating technologies, and safe drug delivery systems. Its products are designed to improve vascular healing and reduce complications associated with traditional stents. With a strong presence in hospitals and cardiac centers worldwide, B. Braun continues to expand its cardiovascular portfolio through research and strategic collaborations.

 

4. Biotronik SE & Co. KG

Headquarters: Berlin, Germany

Biotronik SE & Co. KG specializes in cardiovascular and endovascular medical devices, including drug-coated balloon technologies. The company is known for its advanced engineering and focus on improving patient outcomes through innovative interventional solutions. Its drug-eluting balloons are designed to provide consistent drug transfer and effective treatment of coronary artery disease. Biotronik’s global footprint and commitment to clinical excellence make it a key contributor to advancements in interventional cardiology.

 

5. Terumo Corporation

Headquarters: Tokyo, Japan

Terumo Corporation is a prominent global medical device company offering a wide range of cardiovascular solutions, including advanced balloon catheter technologies. The company focuses on precision engineering and innovative drug delivery systems to enhance the effectiveness of coronary interventions. Its drug-eluting balloon products are widely used in treating complex coronary conditions and improving procedural outcomes. Terumo’s strong presence in the Asia Pacific and expanding global operations position it as a key player in the coronary drug eluting balloon market.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Coronary Drug Eluting Balloon Market.

 

Are you ready to discover more about the Coronary Drug Eluting Balloon market?

The report provides an in-depth analysis of the leading companies operating in the Coronary Drug Eluting Balloon market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Company Profiles

1. Medtronic plc

• Business Overview
• Company Snapshot
• Products Overview
• Company Market Share Analysis
• Company Coverage Portfolio
• Financial Analysis
• Recent Developments
• Merger and Acquisitions
• SWOT Analysis

2.    Boston Scientific Corporation
3.    B. Braun Melsungen AG
4.    Biotronik SE & Co. KG
5.    Terumo Corporation
6.    Koninklijke Philips N.V.
7.    Cardionovum GmbH
8.    iVascular S.L.U.
9.    Biosensors International Group, Ltd.
10.    Others.
 

Conclusion

The Coronary Drug Eluting Balloon market is poised for substantial growth driven by the rising prevalence of cardiovascular diseases, increasing demand for minimally invasive procedures, and growing preference for “leave-nothing-behind” treatment strategies. The market is highly competitive, with leading companies focusing on technological advancements in drug coating, improved delivery mechanisms, and next-generation balloon designs to enhance clinical outcomes. Increasing adoption in treating in-stent restenosis and complex coronary lesions further strengthens market expansion. Additionally, supportive government initiatives, expanding healthcare infrastructure, and rising awareness in emerging economies are accelerating adoption globally. Strategic collaborations, continuous product launches, and ongoing clinical trials are expected to intensify competition and innovation. Overall, the market is set to witness sustained growth, supported by advancements in interventional cardiology and the shift toward safer and more efficient coronary treatment solutions during the forecast period 2026–2035.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Coronary Drug Eluting Balloon Market.

 

Our Reports:

Asia Pacific Blowing Agent Market Size, Scope, Trend to 2035
Japan Health Supplements Market Size, Growth, Scope to 2035
Australia Commercial Vacuum Cleaner Market Size, Demand to 2035
Europe Ethanol Derivatives Market Size, Scope, Growth to 2035

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI. Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter